FDA Approves Blenrep, 1st of Its Kind, for Heavily Pretreated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf), a first-in-class treatment for heavily pretreated adults with relapsed or refractory multiple myeloma, its developer, GlaxoSmithKline, announced. The approval is specific for people who have been given at least four previous…